Olema posts big gain after $209M IPOShares of Olema Pharmaceuticals Inc. (NASDAQ:OLMA) rose $30 (158%) to $49 in their first day of trading after the company raised $209 million through the sale of 11 million...

DISEASE CATEGORY: Cancer INDICATION: Brain cancer An HDAC and LSD1 inhibitor could treat diffuse intrinsic pontine glioma, a subtype of pediatric brain cancer. A dual HDAC and LSD1 inhibitor tool compound, derived from the HDAC...

Drug developers signing up to partner with Atomwise for hit discovery and lead optimization said deal structures made it attractive to take the plunge on the AI company's emerging technology. Last week, Atomwise Inc. announced...

A new crop of companies is creating tools to systematize development of allosteric protein inhibitors, finally moving industry beyond the one-off compounds that have been found by accident. Allosteric pockets on proteins have long been...

A growing crop of researchers and companies are tackling cancer drug resistance by preempting tumors’ tendencies to adapt, rather than responding to resistance after it develops. Though still in their infancy, these therapies could get...

Imago raised $40 million Thursday in a tranched series B round led by new investor Omega Funds to support completing Phase II trials of its lead compound, IMG-7289, for hematological indications. An Imago BioSciences Inc....

An Institute for Research in Biomedicine team has shown increasing chromatin accessibility in cancer could promote tumor aggressiveness, not reduce tumor mutation burden (TMB) as previously thought. The findings, reported last month in Nature Cell...

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....

FDA is looking ahead of industry in its guideline on targets for pediatric oncology, which includes more than 50 not yet in company pipelines in a list of over 220 the agency has its eye...

INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting KDM4B alone or in combination with PI3K could help treat PTEN-deficient triple-negative breast cancer (TNBC). In a PTEN-deficient TNBC cell line, two siRNAs against KDM4B...